1. Home
  2. BWAY vs TNXP Comparison

BWAY vs TNXP Comparison

Compare BWAY & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BWAY
  • TNXP
  • Stock Information
  • Founded
  • BWAY 2003
  • TNXP 2007
  • Country
  • BWAY Israel
  • TNXP United States
  • Employees
  • BWAY N/A
  • TNXP N/A
  • Industry
  • BWAY Medical/Dental Instruments
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • BWAY Health Care
  • TNXP Health Care
  • Exchange
  • BWAY Nasdaq
  • TNXP Nasdaq
  • Market Cap
  • BWAY 280.7M
  • TNXP 335.6M
  • IPO Year
  • BWAY 2019
  • TNXP N/A
  • Fundamental
  • Price
  • BWAY $15.02
  • TNXP $22.98
  • Analyst Decision
  • BWAY Strong Buy
  • TNXP Buy
  • Analyst Count
  • BWAY 2
  • TNXP 1
  • Target Price
  • BWAY $18.00
  • TNXP $70.00
  • AVG Volume (30 Days)
  • BWAY 61.1K
  • TNXP 1.1M
  • Earning Date
  • BWAY 11-11-2025
  • TNXP 11-11-2025
  • Dividend Yield
  • BWAY N/A
  • TNXP N/A
  • EPS Growth
  • BWAY 679.98
  • TNXP N/A
  • EPS
  • BWAY 0.11
  • TNXP N/A
  • Revenue
  • BWAY $46,084,000.00
  • TNXP $9,831,000.00
  • Revenue This Year
  • BWAY $335.63
  • TNXP $14.79
  • Revenue Next Year
  • BWAY $22.10
  • TNXP $933.49
  • P/E Ratio
  • BWAY $55.30
  • TNXP N/A
  • Revenue Growth
  • BWAY 26.50
  • TNXP N/A
  • 52 Week Low
  • BWAY $7.84
  • TNXP $6.76
  • 52 Week High
  • BWAY $17.00
  • TNXP $130.00
  • Technical
  • Relative Strength Index (RSI)
  • BWAY 48.22
  • TNXP 30.96
  • Support Level
  • BWAY $14.65
  • TNXP $23.60
  • Resistance Level
  • BWAY $15.60
  • TNXP $29.19
  • Average True Range (ATR)
  • BWAY 0.67
  • TNXP 1.72
  • MACD
  • BWAY -0.11
  • TNXP 0.10
  • Stochastic Oscillator
  • BWAY 29.79
  • TNXP 7.59

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: